Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Shares Outstanding (Diluted Average) (2023 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Shares Outstanding (Diluted Average) for 3 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 115.28% to $3.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.4 million, a 115.28% increase, with the full-year FY2025 number at $1.6 million, changed N/A from a year prior.
  • Shares Outstanding (Diluted Average) was $3.4 million for Q4 2025 at Neuphoria Therapeutics, up from $2.2 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $981.6 million in Q2 2023 to a low of $1.3 million in Q3 2024.
  • A 3-year average of $141.9 million and a median of $1.7 million in 2025 define the central range for Shares Outstanding (Diluted Average).
  • Biggest YoY gain for Shares Outstanding (Diluted Average) was 115.28% in 2025; the steepest drop was 72.77% in 2025.
  • Neuphoria Therapeutics' Shares Outstanding (Diluted Average) stood at $981.6 million in 2023, then crashed by 99.84% to $1.6 million in 2024, then soared by 115.28% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Shares Outstanding (Diluted Average) are $3.4 million (Q4 2025), $2.2 million (Q3 2025), and $1.6 million (Q2 2025).